Esperion Therapeutics
Sheldon is an accomplished leader in the cardiovascular space and brings over 25 years of experience to Esperion. Most recently, he was a chief commercial officer at Portola Pharmaceuticals. Prior to joining Portola, Sheldon was senior vice president and head of the cardiovascular franchise for Sanofi, where he led U.S. business operations and product launches in more than 20 countries. Previously, he served as vice president and global brand leader for the cardiovascular division of Merck where he took on roles of increasing responsibility within the cardiovascular and thrombosis franchises for more than 25 years, and led marketing for the launch of ezetimibe.
Sheldon holds a Master of Business Administration from Monmouth University and a Bachelor of Applied Science from Drexel University. He also completed the leadership program at The Wharton School of the University of Pennsylvania.
This person is not in any offices
Esperion Therapeutics
2 followers
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at ESPERION is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.